CLINICAL_TRIALS
trial_result
· 2025-05-25
Clinical Trial Update: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease [Phase 3]
Summary
The Phase 3 trial of simufilam 100 mg for mild-to-moderate Alzheimer's disease has completed, with results posted on 2025-05-25.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cassava Sciences, Inc. | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-05-25